PFE - Pfizer Inc.
41.40 -0.02 (-0.05%)
After hours: 5:18PM EDT
| Previous Close | 41.16 |
| Open | 41.23 |
| Bid | 41.40 x 800 |
| Ask | 41.47 x 800 |
| Day's Range | 41.07 - 41.47 |
| 52 Week Range | 32.32 - 41.64 |
| Volume | 15,475,705 |
| Avg. Volume | 20,149,007 |
| Market Cap | 242.289B |
| Beta | 0.96 |
| PE Ratio (TTM) | 11.06 |
| EPS (TTM) | 3.74 |
| Earnings Date | Oct 29, 2018 - Nov 2, 2018 |
| Forward Dividend & Yield | 1.36 (3.33%) |
| Ex-Dividend Date | 2018-08-02 |
| 1y Target Est | 40.60 |
Market Realist•1 hour agoFDA Approves Teva’s Generic Version of EpiPen, Stock Up 7.5%
Today, Teva Pharmaceutical Industries (TEVA) received FDA approval for the generic version of Mylan’s (MYL) allergy products EpiPen and EpiPen Jr. The epinephrine autoinjector is used to treat allergic reactions, including life-threatening condition of anaphylaxis. The company received FDA approval for the use of the product in adults as well as children weighing more than 33 pounds. In 2016, Teva’s generic version of EpiPen was unable to secure FDA approval.
- Motley Fool•9 hours ago
3 Terrible Reasons to Sell Pfizer Stock
Pfizer's shares have been heating up, but now isn't the time to take profits. Here's why.
Market Realist•9 hours agoMYL Stock Down ~3% since Its Q2 2018 Results on August 8
The closing price for Mylan (MYL) stock on August 10 was $37.21, and its market capitalization stood at $19.2 billion. The stock registered its 52-week high of $47.82 on January 23 and its 52-week low of $29.39 on August 15, 2017. Currently, MYL stock is trading above its 50-day moving average of $36.80 but below its 200-day moving average of $39.52. On August 8, MYL stock had declined as much as 7.2% on disappointing second-quarter results that missed analysts’ estimates.
Market Realist•10 hours agoMost Analysts Are Optimistic about Vertex Pharmaceuticals
How Is Vertex Pharmaceuticals Positioned in August? On February 12, the FDA approved Vertex Pharmaceuticals’ (VRTX) Symdeko, which is the company’s third cystic fibrosis drug in the US market. Symdeko continues to witness a strong launch in the US market, and demand has risen across the entire range of eligible patients.
Markit•10 hours agoSee what the IHS Markit Score report has to say about Pfizer Inc.
Pfizer Inc NYSE:PFE
- CNBC•11 hours ago
Stocks making the biggest moves premarket: WMT, JD, JCP, BA, CSCO & more
Comparable-store sales at Walmart U.S. stores rose 4.5 percent from a year earlier, well above the consensus estimate of 2.4 percent. JD.com JD – The China-based internet retailer missed estimates on both the top and bottom lines in its second-quarter earnings report. Investors appear to be focusing on slowing revenue growth rates, with the second quarter's 31.2 percent growth well below the peak of about 60 percent registered in 2015.
- Motley Fool•11 hours ago
Should Gilead Be Worried About This New Monthly HIV Medication?
The devil is in the undisclosed details.
- The Wall Street Journal•11 hours ago
[$$] Pfizer, BioNTech in $425 Million Flu Vaccine Collaboration
BioNTech said it will receive $120 million in upfront payments from Pfizer, along with up to $305 million in potential milestone payments. The Mainz, Germany, company said it will also receive up to double-digit tiered royalty payments on worldwide sales if the program reaches commercialization. BioNTech and Pfizer will jointly conduct research-and-development activities on mRNA-based flu vaccines, the companies said.
- Financial Times•16 hours ago
[$$] Teva shares climb after FDA approves its generic EpiPen
got a shot in the arm on Thursday from the long-awaited approval by US regulators of its generic version of Mylan’s EpiPen allergy injector. Teva’s New York-listed shares were up 6 per cent to $23.83 after the US Food and Drug Administration gave the go-ahead to the Israel-based company.
- Reuters•17 hours ago
Pfizer bets on biotech flu vaccine in $425 million BioNTech alliance
Pfizer (PFE.N) has agreed to pay German biotech firm BioNTech up to $425 million (£334.33 million) in an alliance to develop more effective influenza jabs, the latest among several major pharma companies to bank on a promising new genetic approach. Privately-held BioNTech will receive $120 million upfront plus up to $305 million depending on certain development achievements as well as tiered royalties on futures sales in the double-digit percentage range, the two companies said in a statement on Thursday. Mainz-based BioNTech, valued at $2.3 billion in a January financing round, is specialising in so-called messenger RNA (mRNA) molecules that instruct human cells to produce therapeutic proteins or to launch an immune response.
- Reuters•17 hours ago
Pfizer bets on biotech flu vaccine in $425 mln BioNTech alliance
Pfizer has agreed to pay German biotech firm BioNTech up to $425 million in an alliance to develop more effective influenza jabs, the latest among several major pharma companies to bank on a promising new genetic approach. Privately-held BioNTech will receive $120 million upfront plus up to $305 million depending on certain development achievements as well as tiered royalties on futures sales in the double-digit percentage range, the two companies said in a statement on Thursday. Mainz-based BioNTech, valued at $2.3 billion in a January financing round, is specialising in so-called messenger RNA (mRNA) molecules that instruct human cells to produce therapeutic proteins or to launch an immune response.
- Investor's Business Daily•yesterday
FANG Stocks Take Heat As Distribution Hits Nasdaq; Netflix Slumps 3.5%
FANG stocks were down sharply in afternoon trading Wednesday, with shares of Netflix and Google parent Alphabet down more than 2%.
- Bloomberg•yesterday
A Rare Genetic Aversion to Sweets Could Be Key to Fighting Obesity
People who have a rare genetic mutation called essential fructosuria lack the primary enzyme needed to metabolize fructose, a natural sugar found in honey, fruits and vegetables. No ill consequences have been linked to the defect, save for an aversion to sweets, and it appears to have a significant benefit: Those who have it seem to be at little risk of obesity, type 2 diabetes or serious liver ailments. “When I started contacting people who were taking care of these patients, there was literally no one — I couldn’t find anyone — who was fat or had type 2 diabetes,” said Richard Johnson, a pioneering metabolic-disease scientist at the University of Denver.
- TheStreet.com•yesterday
Buy Stocks That Are Down, Not Up, Here
Take a pass on stocks like Kimberly-Clark or Pfizer that are bucking Wednesday's sell-off and going higher.
- Motley Fool•yesterday
3 Hurdles Ahead of Alnylam and Its Revolutionary New Drug
An FDA approval is a big step, but some big challenges remain.
Market Realist•yesterdayNovo Nordisk’s Biopharmaceuticals Segment: An Update
Novo Nordisk’s (NVO) biopharmaceuticals segment generated revenues of 4.4 billion Danish kroner in the second quarter of 2018, a ~4% YoY (year-over-year) decline in local currencies.
- Motley Fool•yesterday
What's Next for Spark Therapeutics
This gene therapy biotech has its sights set on a second commercial-stage opportunity
Market Realist•2 days agoPfizer Expected to Report Robust EPS Rise in Fiscal 2018
In its Q2 2018 earnings conference call, Pfizer (PFE) updated its fiscal 2018 adjusted diluted earnings per share (or EPS) guidance from the previously projected range of $2.90–$3.00 to $2.95–$3.05. The midpoint of this updated EPS range implies a year-over-year (or YoY) rise of around 13%. While the company has completed share repurchases worth $6.1 billion to date in 2018, Pfizer has not factored in the impact of any additional share repurchases in its adjusted diluted EPS prediction for fiscal 2018. The company expects dilution due to share-based employee compensation to partly offset the impact of share repurchases in fiscal 2018.
Market Realist•2 days agoHow IBM’s Global Business Services Unit Is Doing
IBM’s (IBM) Global Business Services unit, which represents ~21% of its total business, comprises its consulting, global business services, and application management offerings. In the last five quarters, the segment has grown 0.6% compounded annually, driven by improvement in its consulting business.
Market Realist•2 days agoPfizer Is Expected to Report Modest Revenue Rise in Fiscal 2018
In its Q2 2018 earnings conference call, Pfizer (PFE) updated its fiscal 2018 revenue guidance from the previously projected range of $53.5 billion–$55.5 billion to $53.0 billion–$55.0 billion, mainly to account for the unfavorable foreign currency fluctuations from mid-April 2018 to mid-July 2018. Analysts have projected Pfizer’s fiscal 2018 revenues to come in around $54.2 billion, which would be a year-over-year (or YoY) rise of approximately 3.1%. Merck (MRK), Eli Lilly (LLY), and Novartis (NVS) are expected to report revenues close to $42.4 billion, $24.3 billion, and $52.4 billion, respectively, in fiscal 2018.
- Market Realist•3 days ago
How GlaxoSmithKline’s Segments Have Performed
As discussed, GlaxoSmithKline’s three business segments—Pharmaceuticals, Vaccines, and Consumer Healthcare—all saw YoY (year-over-year) revenue growth in the second quarter, as shown in the graph below. Pharmaceuticals revenue fell 3% YoY to ~4.2 billion British pounds, as a result of 1% operating revenue growth and a 4% impact by foreign exchange. ...
- Market Realist•3 days ago
How GlaxoSmithKline’s Valuation Compares with Peers’
Global pharmaceutical company GlaxoSmithKline (GSK) is aiming for sustainable growth by focusing on its business beyond pharmaceuticals. The company, which reports its financial results in British pounds, beat analysts’ EPS and revenue estimates of ~26.1 pence and 7.2 billion pounds in Q2 2018, reporting EPS of 28.1 pence and revenue of 7.3 billion pounds. The chart below shows GlaxoSmithKline’s revenue and EPS since the first quarter of 2017.
Motley Fool•4 days ago3 Beaten-Down Biotech Stocks: Can They Recover?
Is there a light at the end of the tunnel?
Markit•5 days agoSee what the IHS Markit Score report has to say about Pfizer Inc.
Pfizer Inc NYSE:PFE
Motley Fool•6 days agoGlycoMimetics (GLYC) Q2 2018 Earnings Conference Call Transcript
GLYC earnings call for the period ending June 30, 2018.
